Abstract
Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it into the drug development process, and also learning to better manage the expectations of the medical community. Personalized medicine (PM), based on the genetic makeup of a patient, may result in not only an improved therapeutic response but also a clinically important reduction in adverse drug reactions. The experience to date is mixed, with a few successes but many frustrations. This chapter provides an industry perspective on the emergence of the field of PGx focusing on the more mature DNA technologies. Specifically, the chapter will: (1) give a brief description of the history of PGx, (2) provide definitions of key terms, (3) look at the elements in the current healthcare and commercial environment that are driving us to personalized medicine, (4) consider the challenges (strategic/commercial, scientific, regulatory, implementation) that need to be addressed to make PGx and personalized medicine (PM) a reality, and finally, (4) provide a few practical recommendations from an industry perspective for improved success in this area.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Garrod AE (1902) The incidence of alkaptonuria. A study in chemical individuality. Lancet, pp 1616–1620
Haldane, JBS (1949) Disease and evolution. Ric Sci 19:68–75
Kalow W (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6:162–165
Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet pp 576
Bonicke R, Lisboa BP (1957) Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menchen. Naturwissenschaften 44:314–320
Vogel F (1959) Moderne Probleme der Humangenetic. Ergeb Inn Med Kinderheikd 12:52–125.
Mahgoup A, Dring L, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrosiquine in man. Lancet 2:584–586
Eichelbaum M, Spanbrucker N, Steinke B, Dengler HJ (1997) Defective N-oxydation of spartein in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187
Maraz D, Legrand M, Sabbagh N et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evaluation. Pharmacogenetics 7:197–202
Kalow W (2001) Interethnic differences in drug response. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 109–134
Weber WW (2001) Pharmacogenetics-receptors. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 51–80
Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–277
Bondy B (2005) Pharmacogenetics in depression and antidepressants. Dialogues Clin Neurosci 7:223–230
Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7:373–400
Dickins M, Ducker G (2001) Drug disposition: to phenotype or genotype. Int J Pharm Med 15:70–73.
Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapies. Science 206:487–491
Fellay J et al. (2002) Response to antiretroviral treatment in HIV-1 infected individuals with allele variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30–36.
Dubinsky M et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopu-rine therapy in inflammatory bowel disease. Gastroenterology 118:705–713
U.S. FDA. Guidance for industry: pharmacogenomic data submissions. http://www.fda.gov/cder/guidance/6400fnl.pdf. Accessed July 25, 2007
Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S (1996) Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci. 802:101–110
Herceptin product label. http://www.fda.gov/cder/biologics/products/trasgen092598.htm. Accessed July 25, 2007
Erbitux product label. http://www.fda.gov/Cder/drug/infopage/erbitux/default.htm Accessed February 12, 2004
Gleevec revised product label. http://www.fda.gov/CDER/drug/infopage/gleevec/default.htm. Accessed October 30, 2006
Tarceva product label. http://www.fda.gov/cder/foi/label/2004/021743lbl.pdf. Accessed July 25, 2007
Camptosar product label. http://www.fda.gov/cder/foi/label/2006/020571s030lbl.pdf. Accessed July 25, 2007
Strattera product label. http://www.fda.gov/cder/foi/label/2007/021411s004s012s013s015s021lbl.pdf. Accessed July 25, 2007
Purinethol product label. http://www.fda.gov/cder/foi/label/2004/09053s024lbl.pdf. Accessed July 25, 2007
Coumadin product label. http://www.fda.gov/cder/foi/label/2006/009218s102lbl.pdf. Accessed July 25, 2007
Centre for Medicines Research (CMR) International Ltd. (2006) NME output lifts from 20 year low. Thomson Scientific KnowledgeLink Newsletter
Tufts Center for the Study of Drug Development, Outlook 2006
U.S. FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. Accessed on July 25, 2007
Vioxx withdrawal. Merck press release. http://www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf.
Bill S.3822. Genomics and personalized medicine act of 2006. Introduced in U.S. Senate by Barak Obama
Kim MJ et al. (2008) Pharmacogenomics: the regulatory environment and labeling implication. In: Cohen N (ed) Pharmacogenomics and personalized medicine. Humana Press (Springer) Chapter 3
Gutman S, Hackett J (2006) Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side. Pharmacogenomics 7(8):1223–1227
EMEA Pharmacogenomics Working Party. http://www.emea.europa.eu/pdfs/human/pharmacogenetics/10159204en.pdf.
Guiding principles: processing joint FDA-EMEA voluntary genomic data submissions (VGDSs) within the framework of the confidentiality arrangement. http://www.emea.europa.eu/pdfs/general/direct/pr/FDAEMEA.pdf.
ICH terminology in pharmacogenomics (E15). http://www.fda.gov/cder/guidance/7619dft.pdf.
Arcoxia non–approvable. http://www.merck.com/newsroom/press_releases/research_and_development/2007_0427.html.
PhRMABiomarkerConsortium. http://www.innovation.org/index.cfm/NewsCenterBriefings/The_Biomarkers_Consortium.
Predictive Safety Testing Consortium. http://www.fda.gov/bbs/topics/news/2006/NEW01337.html.
Serious Adverse Event Consortium (www.saeconsortium.org).
Industry-Pharmacogenomics Working Group. http://www.i-pwg.org/cms/
Spear B, Heath-Chiozzi M, Barnes D, Cheeseman K, Shaw P, Campbell D (2001) Termi no-logy for sample collection in clinical genetic studies. Pharmacogenomics J 1:101–3
Anderson C, Gomez- Mancilla B, Spear B et al. (2002) Elements of informed consent for phar-macogenetic research: perspective of the Pharmacogenetics Working Group. Pharmacogenomics J 2(5):284–92
Renegar G, Webster C, Stuerzebecher S et al. (2006) Returning genetic research results to individuals: points to consider. Bioethics 20(1):24–36
Personalized Medicine Coalition. http://www.personalizedmedicinecoalition.org/communications/overview.php.
U.S. FDA. Genomics at FDA: table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm. Accessed July 25, 2007
Lesko LJ. (2007) Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 81:807–816
Point of Care Diagnostic Dr Nakamura accessed at http://www.twt.com/company/press-releases/2006/March_2_2006.htm.
National Coalition for Health Professional Education in Genetics (NCHPEG). http://www.nchpeg.org/.
Council for International Organizations of Medical Sciences (CIOMS) (2002) International Ethical Guidelines for Biomedical Research Involving Human Subjects accessed at http://www.cioms.ch/frame_guidelines_nov_2002.htm.
Nuffield council report on bioethics of pharmacogenetics. http://www.nuffieldbioethics.org/filelibrary/paf1/pharmacogenetics_report.pdf.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Cohen, N., Frangiosa, T. (2008). Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine. In: Cohen, N. (eds) Pharmacogenomics and Personalized Medicine. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-439-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-59745-439-1_1
Publisher Name: Humana Press
Print ISBN: 978-1-934115-04-6
Online ISBN: 978-1-59745-439-1
eBook Packages: Springer Protocols